Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
261 Results for "
aggregate
" in MedChemExpress (MCE) Product Catalog:
Products (261)
261 Results for "aggregate" in MCE Product Catalog:
Cat. No.: HY-P992451
Synonyms: KY1066
Research Areas:
Cat. No.: HY-117710B
CAS No.: 1531586-64-7
Research Areas:
AD-35 is an orally active, blood-brain barrier-permeable acetylcholinesterase inhibitor with an IC50 of 793 nM. AD-35 inhibits metal-induced amyloid-β aggregation and disassembles preformed amyloid-β aggregates. In rat models of cognitive impairment, AD-35 attenuates Aβ25-35-induced astrocyte activation, TNF-α and IL-1β release, inhibits ERK phosphorylation, and alleviates learning and memory deficits. AD-35 can be used for research on Alzheimer's disease .
Cat. No.: HY-184602
Gold nanoclusters (AuNCs) are molecular-level aggregates consisting of a core of several to dozens of gold atoms, protected by organic monomers such as thiol compounds or proteins. GSH-AuNCs utilize glutathione (a thiol-containing tripeptide) as both a reducing agent and a protecting group, reacting chemically with gold atoms to form nanoclusters, representing a transitional state between metal atoms and metal nanoparticles. Due to size effects and the emergence of quantized energy levels, GSH-AuNCs possess unique optical properties, such as tunable fluorescence emission spectra. Their fluorescence emission wavelength can be tuned with variations in particle size and composition.
Cat. No.: HY-184817
CAS No.: 2883627-63-0
Research Areas:
α-Synuclein-IN-22 is an α-Synuclein inhibitor with an IC50 of 2.7 μM against human α-Syn. α-Synuclein-IN-22 exerts anti-aggregation effects by stabilizing the native conformation of α-Syn, inhibiting the formation of β-sheet aggregates and inclusion bodies, and dissociating mature fibrils into functional monomers. α-Synuclein-IN-22 scavenges ROS and shows low cytotoxicity. α-Synuclein-IN-22 can be used in research related to Parkinson's disease .
Cat. No.: HY-184819
CAS No.: 2883627-56-1
Research Areas:
α-Synuclein-IN-24 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 4.0 μM. α-Synuclein-IN-24 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks reaggregation. α-Synuclein-IN-24 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-24 can be used for the research of Parkinson's disease .
Cat. No.: HY-P3688A
Synonyms: Aβ (1-38) TFA; Aβ38 TFA
Target:
Research Areas:
Cat. No.: HY-123745
CAS No.: 439932-74-8
Target:
Research Areas:
Aβ aggregation-IN-6 is an Aβ aggregation inhibitor with ~60-70% inhibition of Aβ17-40 aggregation. Aβ aggregation-IN-6 stabilizes Aβ dimer assembly, binds to Aβ steric-zipper assembly. Aβ aggregation-IN-6 can be used for the research of alzheimer's disease .
Cat. No.: HY-149430
CAS No.: 2446054-34-6
Target:
Research Areas:
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .
Cat. No.: HY-123366
CAS No.: 70386-06-0
Target:
Research Areas:
Y-590 is an orally active platelet cyclic adenosine monophosphate phosphodiesterase (cAMP-PDE) inhibitor with an IC50 of 0.9 nM against rabbit cAMP-PDE. Y-590 inhibits platelet aggregation, disaggregates aggregated platelets, suppresses collagen-induced platelet release, reduces platelet retention and inhibits cAMP degradation in platelets. Y-590 enhances PGI2-mediated elevation of intracellular cAMP in platelets and exerts a synergistic effect with PGI2 on ADP-induced platelet aggregation. Y-590 can be used in studies related to thrombotic diseases and thrombosis .
Cat. No.: HY-147658
CAS No.: 1321361-13-0
Research Areas:
AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.058, 0.082 and 0.115 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-1 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-1 has remarkable antioxidant potential .
Cat. No.: HY-147659
CAS No.: 1877000-20-8
Research Areas:
AChE/BChE/BACE-1-IN-2 (Compound 4o) is an orally active inhibitor of AChE, BChE, and BACE-1 with IC50 values of 0.069, 0.127 and 0.097 μM against hAChE, hBChE and hBACE-1, respectively. AChE/BChE/BACE-1-IN-2 shows considerable PAS-AChE binding capability, excellent brain permeation, potential disassembly of Aβ aggregates, and neuroprotective activity against Aβ-induced stress. AChE/BChE/BACE-1-IN-2 has remarkable antioxidant potential .
Cat. No.: HY-174305
Target:
Research Areas:
Aβ42-IN-7 (Compound CT-01) is a brain-penetrant and selective amyloid-β42 (Aβ42) inhibitor. Aβ42-IN-7 inhibits Aβ42’s assembly into neurotoxic soluble oligomers and extracellular fibrillary aggregates. Aβ42-IN-7 exerts neuroprotective effects by reducing amyloid-mediated neuronal toxicity. Aβ42-IN-7 can be used in research on Alzheimer’s disease (AD) .
Cat. No.: HY-B0512S1
CAS No.: 1196157-80-8
Synonyms: RP2632-13C6
Cat. No.: HY-D3130
Target:
Research Areas:
Mem-pH is a ratiometric fluorescent probe used for measuring vesicular pH. Mem-pH inserts into the plasma membrane bilayer and localizes to the vesicular lumen, switching between its basic and acidic forms via protonation during vesicular acidification to enable ratiometric pH readout. In aqueous media, Mem-pH forms non-emissive aggregates through aggregation-induced quenching, and then depolymerizes and recovers its fluorescent activity upon binding to the plasma membrane. The excitation/emission wavelengths of the basic form of Mem-pH are 405/450-550 nm, while those of the acidic form are 488/500-700 nm .
Cat. No.: HY-P2260B
Cat. No.: HY-P2260C
Cat. No.: HY-117710A
CAS No.: 1531586-58-9
Research Areas:
AD-35 free base is an orally active, blood-brain barrier-permeable acetylcholinesterase inhibitor with an IC50 of 793 nM. AD-35 free base inhibits metal-induced amyloid-β aggregation and disassembles preformed amyloid-β aggregates. In rat models of cognitive impairment, AD-35 free base attenuates Aβ25-35-induced astrocyte activation, TNF-α and IL-1β release, inhibits ERK phosphorylation, and alleviates learning and memory deficits. AD-35 free base can be used for research on Alzheimer's disease .
Cat. No.: HY-125172
CAS No.: 300670-16-0
Synonyms: Polyglutamine Aggregation inhibitor III
Target:
Research Areas:
C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
